Delivery Order SPE2DR25D9239-SPE2DR26FFBN5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $27,905.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement....
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The award was issued on November 13, 2025, with an ultimate completion date of December 5, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery...
- The Defense Logistics Agency awarded a $27,905.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a $46,509.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency issued a delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials, a oncology therapeutic product. The order was awarded on December 11, 2025, with an ultimate completion date of January 5, 2026, under a firm fixed-price contract structure with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform work at its Park...
- The Defense Logistics Agency awarded a $41,858.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award...
- The Defense Logistics Agency awarded a delivery order valued at $4,650.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, utilizes firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $79,430.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Perjeta 420 mg/14 mL vials. The award, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation and was issued without subcontractor involvement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite...
- The Defense Logistics Agency awarded a $41,441.33 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency (DLA) awarded a $139,529.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (420 mg/14 mL vials). The delivery order, issued on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical...
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFBN5Delivery Order
The Defense Logistics Agency issued a delivery order valued at $27,905.88 to DMS Pharmaceutical Group Inc. on November 28, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, which carries an ultimate completion date of December 19, 2025, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected as the awardee based on its established performance as a critical supplier within the Department of Defense pharmaceutical supply chain. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors authorized to supply a comprehensive range of pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. Through this vehicle, the Defense Logistics Agency can issue firm fixed-price delivery orders for specialized pharmaceutical products to meet recurring medical supply needs across the global military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 11/27/25 |